West Pharmaceutical Services (NYSE:WST) Reaches New 12-Month High – Still a Buy?

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $333.89 and last traded at $331.6530, with a volume of 31127 shares. The stock had previously closed at $319.75.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on WST shares. Jefferies Financial Group restated a “buy” rating and set a $295.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Morgan Stanley lifted their price objective on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the company an “equal weight” rating in a research note on Friday, May 29th. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Finally, Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $310.00 to $400.00 in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $340.09.

West Pharmaceutical Services Price Performance

The firm has a market capitalization of $23.42 billion, a PE ratio of 44.29, a price-to-earnings-growth ratio of 2.63 and a beta of 1.18. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The business’s 50 day moving average is $292.30 and its two-hundred day moving average is $269.75.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.68 million. During the same period in the previous year, the business earned $1.45 EPS. West Pharmaceutical Services’s revenue was up 21.0% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.

West Pharmaceutical Services declared that its Board of Directors has approved a stock buyback plan on Tuesday, February 17th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 5.6% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Annette F. Favorite sold 2,817 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This trade represents a 14.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Elyxium Wealth LLC bought a new position in West Pharmaceutical Services in the 4th quarter valued at $25,000. Bayban bought a new position in West Pharmaceutical Services in the 4th quarter valued at $27,000. Private Trust Co. NA boosted its holdings in West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 61 shares during the period. DV Equities LLC bought a new position in West Pharmaceutical Services in the 4th quarter valued at $28,000. Finally, Cornerstone Planning Group LLC lifted its holdings in shares of West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 50 shares during the last quarter. 93.90% of the stock is owned by institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.